MA42409A - Oxystérols et leurs procédés d'utilisation - Google Patents
Oxystérols et leurs procédés d'utilisationInfo
- Publication number
- MA42409A MA42409A MA042409A MA42409A MA42409A MA 42409 A MA42409 A MA 42409A MA 042409 A MA042409 A MA 042409A MA 42409 A MA42409 A MA 42409A MA 42409 A MA42409 A MA 42409A
- Authority
- MA
- Morocco
- Prior art keywords
- oxysterols
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189065P | 2015-07-06 | 2015-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42409A true MA42409A (fr) | 2018-05-16 |
Family
ID=57686058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042409A MA42409A (fr) | 2015-07-06 | 2016-07-06 | Oxystérols et leurs procédés d'utilisation |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10696712B2 (fr) |
| EP (2) | EP3319610A4 (fr) |
| JP (3) | JP6882996B2 (fr) |
| AU (2) | AU2016289965B2 (fr) |
| CA (1) | CA2991311C (fr) |
| HK (1) | HK1255500A1 (fr) |
| MA (1) | MA42409A (fr) |
| WO (1) | WO2017007832A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| EP3204011A4 (fr) * | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Composés neuroactifs et leurs procédés d'utilisation |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| CN114272249A (zh) | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3519422B1 (fr) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | Oxystérols substitués en c7 et ces composés pour l'utilisation en tant que modulateurs nmda |
| ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN110628737B (zh) * | 2019-10-14 | 2022-06-07 | 南京农业大学 | 一个调控黄瓜矮化性状相关基因及其应用 |
| WO2022261510A1 (fr) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Stéroïde neuroactif pour le traitement de la maladie d'alzheimer |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) * | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (fr) * | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) * | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) * | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) * | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) * | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) * | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) * | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) * | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) * | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) * | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| NZ282939A (en) | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| JPH08268917A (ja) * | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (fr) * | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Procede de preparation de 27-hydroxy cholesterol et de derives apparentes |
| JPH09328498A (ja) * | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| US8541600B2 (en) * | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) * | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1450816A4 (fr) | 2001-11-08 | 2008-02-13 | Univ Chicago | Methode de traitement de troubles lies a un taux de cholesterol eleve |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| NZ547344A (en) | 2002-03-27 | 2007-11-30 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| WO2004055201A2 (fr) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) utilisee en tant que cible therapeutique pour le traitement de la maladie d'alzheimer |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (fr) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Nouvelle therapie destinee au traitement de maladies cerebrales degeneratives chroniques et d'une lesion du systeme nerveux |
| CA2643732C (fr) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Composes oxysterols et voie |
| WO2008057468A1 (fr) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Régulateurs à petites molécules organiques de la prolifération cellulaires |
| EP2170828B1 (fr) | 2007-06-20 | 2012-11-21 | Auspex Pharmaceuticals, Inc. | N-aryle pyridinones substituees a fonction d'inhibiteurs fibrogenes |
| CA2703497A1 (fr) | 2007-11-06 | 2009-05-14 | N.V. Organon | Procede de diminution du taux d'hormone chez les etres humains |
| WO2009090063A1 (fr) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Dérivés de sapogénine stéroïde, androstane et sapogénine triterpénoïde pour le traitement et la prévention de maladies infectieuses |
| JP2011520815A (ja) * | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| WO2010065709A2 (fr) | 2008-12-03 | 2010-06-10 | Amin Khan | Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
| EP2459581A4 (fr) | 2009-07-29 | 2012-12-26 | Univ Chicago | Agonistes du récepteur x du foie |
| WO2011028794A2 (fr) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Traitement de la chorée de huntington avec de la cyclosérine et un agoniste des récepteurs nmda |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| CN102753019A (zh) * | 2009-12-15 | 2012-10-24 | 纽罗普公司 | 用于治疗神经系统病症的化合物 |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) * | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| EP2714081A4 (fr) | 2011-05-27 | 2015-09-09 | Cytocure Llc | Méthodes, compositions et trousses pour le traitement du cancer |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US20150158903A1 (en) * | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| WO2013163455A2 (fr) | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | Plate-forme de criblage de médicaments pour le syndrome de rett |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| EP2948152A4 (fr) | 2013-01-23 | 2016-12-14 | Sphaera Pharma Private Ltd | Nouveaux composés de 11bêta-hydroxy-stéroïdes destinés à être utilisés utilisation dans la biogenèse de mitochondries et les maladies associées avec la dysfonction ou la déplétion mitochondriale |
| MX2015009773A (es) | 2013-01-29 | 2016-08-05 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| IL286970B2 (en) * | 2013-03-13 | 2024-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of use thereof |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| US10016095B2 (en) * | 2014-10-03 | 2018-07-10 | Progressive International Corporation | Salad spinner |
| EP3204011A4 (fr) * | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Composés neuroactifs et leurs procédés d'utilisation |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| RS62220B1 (sr) * | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| CN110945006A (zh) | 2017-06-23 | 2020-03-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2016
- 2016-07-06 MA MA042409A patent/MA42409A/fr unknown
- 2016-07-06 US US15/742,422 patent/US10696712B2/en active Active
- 2016-07-06 CA CA2991311A patent/CA2991311C/fr active Active
- 2016-07-06 WO PCT/US2016/041160 patent/WO2017007832A1/fr not_active Ceased
- 2016-07-06 HK HK18114684.2A patent/HK1255500A1/zh unknown
- 2016-07-06 EP EP16821920.2A patent/EP3319610A4/fr not_active Withdrawn
- 2016-07-06 JP JP2017568208A patent/JP6882996B2/ja active Active
- 2016-07-06 AU AU2016289965A patent/AU2016289965B2/en active Active
- 2016-07-06 EP EP23199636.4A patent/EP4316591A3/fr active Pending
-
2020
- 2020-05-20 US US16/879,460 patent/US20210101925A1/en not_active Abandoned
-
2021
- 2021-01-07 JP JP2021001453A patent/JP7410062B2/ja active Active
- 2021-08-20 AU AU2021218227A patent/AU2021218227B2/en active Active
-
2022
- 2022-05-20 US US17/749,976 patent/US20230047157A1/en not_active Abandoned
- 2022-07-01 JP JP2022107293A patent/JP7478190B2/ja active Active
-
2024
- 2024-06-18 US US18/746,388 patent/US20250154192A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10696712B2 (en) | 2020-06-30 |
| EP4316591A3 (fr) | 2024-04-24 |
| AU2016289965A1 (en) | 2018-01-18 |
| US20210101925A1 (en) | 2021-04-08 |
| WO2017007832A1 (fr) | 2017-01-12 |
| HK1255500A1 (zh) | 2019-08-16 |
| US20180201643A1 (en) | 2018-07-19 |
| CA2991311A1 (fr) | 2017-01-12 |
| CA2991311C (fr) | 2025-05-06 |
| AU2021218227A1 (en) | 2021-09-09 |
| AU2016289965B2 (en) | 2021-09-09 |
| AU2021218227B2 (en) | 2023-08-03 |
| JP7410062B2 (ja) | 2024-01-09 |
| EP3319610A4 (fr) | 2019-03-06 |
| EP3319610A1 (fr) | 2018-05-16 |
| JP7478190B2 (ja) | 2024-05-02 |
| JP2022130668A (ja) | 2022-09-06 |
| NZ738582A (en) | 2024-10-25 |
| JP2021063118A (ja) | 2021-04-22 |
| JP6882996B2 (ja) | 2021-06-02 |
| JP2018519329A (ja) | 2018-07-19 |
| US20230047157A1 (en) | 2023-02-16 |
| EP4316591A2 (fr) | 2024-02-07 |
| US20250154192A1 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3436048A4 (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3684364A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3298168A4 (fr) | Agents réducteurs stabilisés et leurs procédés d'utilisation | |
| EP3390624A4 (fr) | Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation | |
| EP3307762A4 (fr) | Variants de cas9 rapporteurs et leurs procédés d'utilisation | |
| EP3510040A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| EP3307844A4 (fr) | Fluides de forage et leurs procédés d'utilisation | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3383914A4 (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| EP3416634A4 (fr) | Agents immunomodulateurs et leurs procédés d'utilisation | |
| EP3436030A4 (fr) | Récepteurs chimériques et leurs procédés d'utilisation | |
| EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation | |
| EP3303634A4 (fr) | Variants de cas9 et procédés d'utilisation associés | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA40069A (fr) | Molécules de liaison trispécifiques et leurs procédés d'utilisation | |
| EP3341027A4 (fr) | Complexes de transfection et leurs procédés d'utilisation | |
| MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP2971000A4 (fr) | Polypeptides phi-4 et leurs procédés d'utilisation | |
| EP3349851A4 (fr) | Polypeptides photosensibles et leurs procédés d'utilisation |